Thrombin Glu-39 restricts the P'3 specificity to nonacidic residues

The cofactors heparin, vitronectin (VN), and thrombomodulin (TM) modulate the reactivity of alpha-thrombin with plasminogen activator inhibitor (PAI-1). While heparin and VN accelerate the reaction by approximately 2 orders of magnitude, TM protects alpha-thrombin from rapid inactivation by PAI-1 in the presence of VN. To understand how these cofactors function, we studied the kinetics of PAI-1 inactivation of alpha-thrombin, the exosite 1 variant gamma-thrombin, the exosite 2 mutant R93,97,101A thrombin, and recombinant meizothrombin in both the absence and presence of these cofactors. Heparin and VN accelerated the second-order association rate constant [k(2) = (7.9 +/- 0.5) x 10(2) M(-)(1) s(-)(1)] of alpha-thrombin with PAI-1 approximately 200- and approximately 240-fold, respectively. The k(2) value for gamma-thrombin [(7.9 +/- 0.7) x 10(1) M(-)(1) s(-)(1)] was impaired 10-fold, but was enhanced by heparin and VN approximately 280- and approximately 75-fold, respectively. Similar to inactivation of gamma-thrombin, PAI-1 inactivation of alpha-thrombin in complex with the epidermal growth factor-like domains 4-6 of TM (TM4-6) was impaired approximately 10-fold. The exosite 2 mutant R93,97,101A thrombin, which was previously shown not to bind heparin, and meizothrombin, in which exosite 2 is masked, reacted with PAI-1 at similar rates in both the absence and presence of heparin [k(2) = (1.3-1.5) x 10(3) M(-)(1) s(-)(1) for R93,97,101A thrombin and k(2) = (3.6-5.1) x 10(2) M(-)(1) s(-)(1) for meizothrombin]. Unlike heparin, however, VN enhanced the k(2) of R93,97,101A thrombin and meizothrombin inactivation approximately 80- and approximately 30-fold, respectively. Continuous kinetic analysis as well as competition kinetic studies in the presence of S195A thrombin suggested that the accelerating effect of VN or heparin occurs primarily by lowering the dissociation constant (K(d)) for formation of a noncovalent, Michaelis-type complex. Analysis of these results suggest that (1) heparin binds to exosite 2 of alpha-thrombin to accelerate the reaction by a template mechanism, (2) VN accelerates PAI-1 inactivation of alpha-thrombin by lowering the K(d) for initial complex formation by an unknown mechanism that does not require binding to either exosite 1 or exosite 2 of alpha-thrombin, (3) alpha-thrombin may have a binding site for PAI-1 within or near exosite 1, and (4) TM occupancy of exosite 1 partially accounts for the protection of thrombin from rapid inactivation by PAI-1 in the presence of vitronectin.

Section: Discussionmentioning

confidence: 99%

Role of Exosites 1 and 2 in Thrombin Reaction with Plasminogen Activator Inhibitor-1 in the Absence and Presence of Cofactors

Rezaie

1999

“…Proteins and Reagents. Plasma-derived thrombin , wild-type recombinant thrombin (Le Bonniec et al, 1991), and the des-ETW mutant (Le Bonniec et al, 1992b) were prepared as previously reported. Hirudin (sulfated), isolated from leeches, was a gift from Plantorgan AG (Bad Zwischenahn, Germany).…”

Section: Methodsmentioning

confidence: 99%

Mapping of the Thrombin des-ETW Conformation by Using Site-Directed Mutants of Hirudin. Evidence for the Induction of Nonlocal Modifications by Mutagenesis

Bonniec

Betz²,

Er³

et al. 1994

Deletion of Glu146, Thr147, and Trp148 from thrombin dramatically alters its interactions with substrates, ligands, and inhibitors, and the changes appear to result from nonlocal modification of thrombin's structure [Le Bonniec, B. F., Guinto, E. R., & Esmon, C. T. (1992) J. Biol. Chem. 267, 19341-19348]. In an attempt to localize conformational change in this thrombin mutant (des-ETW), its affinity for 43 site-directed mutants of hirudin have been compared with that of native thrombin. The inhibition constants (KI) of recombinant and natural hirudin with des-ETW were found to be approximately 2300-fold higher than those with thrombin. The reduced affinity was predominantly the result of an increase in the dissociation rate constant rather than a decrease in the association rate constant. For most of the hirudin mutants tested, the difference in binding energy between thrombin and des-ETW [delta delta Gbo(IIa-ETW)] was about 19.9 kJ mol-1 and comparable to that of hirudin; in particular, all mutations in the C-terminal region of the inhibitor did not affect delta delta Gbo(IIa-ETW). Thus, the conformation of thrombin's anion-binding exosite seems unaltered by the des-ETW mutation. In contrast, hirudin substitutions involving Val1', Val2', Thr4', Asp5', and Ser19', as well as the addition of an N-terminal glycine, resulted in values of delta delta Gbo(IIa-ETW) which were 2 to 10 kJ mol-1 lower than that for hirudin. Furthermore, a Leu15'-->Ala hirudin mutant behaved with des-ETW, as a partial competitive inhibitor rather than a tight-binding inhibitor, in contrast to all other hirudin variants tested.(ABSTRACT TRUNCATED AT 250 WORDS)

“…It is therefore not known whether the improvement in the reactivities of the mutants with PAI-1 is due to an effect on the first step or the second step of the reaction. However, previous kinetic studies have indicated that E192Q and E39K thrombins activate protein C, the natural substrate of thrombin in the anticoagulant pathway, 22-and 2-fold faster than wild-type thrombin, respectively (15,24). In both cases, the improvements in the activation rates were localized to the second step of the reaction, i.e., in the k cat of the protein C activation (15,24).…”

Section: Discussionmentioning

confidence: 85%

“…However, previous kinetic studies have indicated that E192Q and E39K thrombins activate protein C, the natural substrate of thrombin in the anticoagulant pathway, 22-and 2-fold faster than wild-type thrombin, respectively (15,24). In both cases, the improvements in the activation rates were localized to the second step of the reaction, i.e., in the k cat of the protein C activation (15,24). These previous studies proposed a crucial role for Glu192 and Glu39 in determination of the S3 and S3′ binding specificity of thrombin, respectively (22,24,29).…”

Section: Discussionmentioning

confidence: 92%

“…Proteins and Reagents. The prethrombin 1 forms of the wild-type and mutant proteins were expressed in mammalian cells, purified to homogeneity, activated to thrombin, and active-site-titrated as previously described (12,15). Recombinant active human PAI-1 (product PAI-A, 95 ( 5% active as titrated by uPA) was obtained from Molecular Innovations, Inc. (Royal Oak, MI).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Elucidation of the Structural Basis for the Slow Reactivity of Thrombin with Plasminogen Activator Inhibitor-1

Rezaie

1998

Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor of the serpin superfamily which rapidly inactivates tissue plasminogen activator (tPA), but reacts with thrombin at a much slower rate. Based on the previous mutagenesis studies and the X-ray crystal structure of the thrombin E192Q-bovine pancreatic trypsin inhibitor (BPTI) complex, the structural basis for the slow reactivity of thrombin with PAI-1 is investigated in this study. In the crystal structure of the thrombin E192Q-BPTI complex, the reactive site loop of BPTI is stabilized in a canonical conformation by several productive interactions (e.g., Glu39 of thrombin is ion-paired to the P5' Arg, and Gln192 is hydrogen-bonded to the P2 and P4 backbone carbonyls of BPTI). PAI-1 contains Glu residues at both the P4' and P5' positions, and previous mutagenesis studies suggest that these residues make productive interactions with Arg39 of tPA as well as with two other positively charged residues present on the 39-loop of the protease (chymotrypsin numbering). Glu39 and Glu192 of thrombin would be unable to make such productive interactions with PAI-1. Instead, their repulsive interactions with the similarly charged residues and/or the backbone carbonyls of the PAI-1 reactive site loop could restrict the reaction. To test this, the rate constants (k2) for the PAI-1 inactivation of wild-type, E39K, E39Q, E192Q, E192M, and E39K/E192Q thrombins were determined. The inactivation rates of E39K [k2 = (4.3 +/- 0.2) x 10(4) M-1 s-1] and E39Q [k2 = (1.0 +/- 0.1) x 10(4) M-1 s-1] were 50- and 12-fold faster than the inactivation of wild-type thrombin [k2 = (8.6 +/- 0. 5) x 10(2) M-1 s-1], respectively. Relative to thrombin, the PAI-1 inactivation rates were improved 31-fold for E192Q [k2 = (2.7 +/- 0. 5) x 10(4) M-1 s-1] and 5-fold for E192M [k2 = (4.3 +/- 0.8) x 10(3) M-1 s-1] thrombins. With the double mutant E39K/E192Q, the inactivation rate [k2 = (5.4 +/- 0.4) x 10(5) M-1 s-1] was improved 628-fold over wild-type thrombin. These results suggest that repulsive interactions and/or lack of productive electrostatic interactions between PAI-1 and Glu39 and Glu192 of thrombin are responsible for the slow reaction of thrombin with this serpin.